Phosphorylated H2AX in Noninvasive Low Grade Urothelial Carcinoma of the Bladder: Correlation With Tumor Recurrence

Journal of Urology

Volumn 181, Issue 3, 2009, Pages 1387-1392

  Cheung, Wang L ^a   Albadine, Roula ^a   Chan, Theresa ^b   Sharma, R ^a   Netto, George J ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

epigenesis; genetic; histones; urinary bladder; urinary bladder neoplasms; urothelium

Indexed keywords

DNA; GAMMA HISTONE H2AX; HISTONE H2AX; POLYCLONAL ANTIBODY; SERINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HISTONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 59349089679     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.10.146     Document Type: Article

References (17)

1. Pashos C.L., Botteman M.F., Laskin B.L., and Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 10 (2002) 311
2. Parekh D.J., Bochner B.H., and Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol 24 (2006) 5519
3. Holmang S., Hedelin H., Anderstrom C., Holmberg E., Busch C., and Johansson S.L. Recurrence and progression in low grade papillary urothelial tumors. J Urol 162 (1999) 702
4. Wu J., and Grunstein M. 25 Years after the nucleosome model: chromatin modifications. Trends Biochem Sci 25 (2000) 619
5. Cheung W.L., Briggs S.D., and Allis C.D. Acetylation and chromosomal functions. Curr Opin Cell Biol 12 (2000) 326
6. Santos-Rosa H., and Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41 (2005) 2381
7. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864
8. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262
9. Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I.A. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (2004), IARCC Press, Lyons
10. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844
11. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5 (2005) 713
12. Spruck III C.H., Ohneseit P.F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y.C., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784
13. Ishikawa J., Xu H.J., Hu S.X., Yandell D.W., Maeda S., Kamidono S., et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51 (1991) 5736
14. Catto J.W., Xinarianos G., Burton J.L., Meuth M., and Hamdy F.C. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 105 (2003) 484
15. Fillingham J., Keogh M.C., and Krogan N.J. GammaH2AX and its role in DNA double-strand break repair. Biochem Cell Biol 84 (2006) 568
16. Ku J.H., Kwak C., Lee H.S., Park H.K., Lee E., and Lee S.E. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171 (2004) 631
17. Shariat S.F., Tokunaga H., Zhou J., Kim J., Ayala G.E., Benedict W.F., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014